Quartesian Surpasses 250 Studies Employing Medrio's EDC Platform News provided by Share this article Share this article PRINCETON, N.J., May 4, 2021 /PRNewswire/ -- Quartesian, a multinational Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, announced today that they have deployed Medrio's cloud-based EDC platform for 265 clinical studies world-wide. Quartesian's partnership with Medrio began in 2009 and they were an early participant in the Medrio Partner Program providing expanded services to better support mutual sponsor and CRO customers. Quartesian has contributed to both product development and marketing during this long relationship as part of Medrio's Customer Advisory Board. "Quartesian and Medrio understand the value of data-driven trials. Surpassing 250 studies together means that the data speaks for itself," said Nicole Latimer, CEO of Medrio. "Quartesian continues to disrupt the clinical data services industry by unlocking data-driven insights that help clinical teams take back control of their studies. Medrio is proud to provide the scalable, unified solutions that power these insights and bring us closer to medical breakthroughs."